We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Real-world evidence · Open methodology
Most menopause telehealth companies publish testimonials. We publish protocol. This is the fixed, pre-registered standard by which Kindr Health measures and reports whether our care actually works — declared before the first result, so the results mean something when they arrive.
No outcome figures appear on this page yet, and none will until a pre-registered cohort completes follow-up. Any clinic quoting effectiveness percentages without a cohort, a denominator, and a follow-up rate is quoting marketing, not evidence.
Declared August 1, 2026. These do not change between cohorts. If we ever add an endpoint, the addition is dated and the original list stays visible.
| Tier | Measure | Instrument | Measurement window |
|---|---|---|---|
| Primary endpoint | Vasomotor symptom burden at 12 weeks | Menopause Rating Scale (MRS) — hot flash / sweating item | Baseline, week 4, week 12 |
| Secondary | Sleep quality change | Single-item sleep disturbance rating (0–10) | Baseline, week 4, week 12 |
| Secondary | Mood and cognitive symptom change | MRS psychological subscale | Baseline, week 12 |
| Secondary | Treatment persistence | Proportion still on therapy at 12 and 24 weeks | Week 12, week 24 |
| Safety | Adverse events and discontinuation reasons | Clinician-coded reports from our pharmacovigilance intake | Continuous |
The measures below are fixed and published in advance. We do not choose our endpoints after seeing which numbers look best — that is the single most common way telehealth outcome claims become marketing.
Every reported result carries the full cohort size, the number lost to follow-up, and the number excluded — so a reader can recompute our percentages themselves.
If a secondary endpoint shows no benefit, it is published with the same prominence as one that does. Selective reporting is disqualifying for a clinic that asks to be trusted with prescribing.
Nothing is published below a cell size of 20 patients. No free-text, no dates of service, no geography finer than state. See our data ethics policy for the full standard.
Full governance standard: data ethics policy. Safety reporting intake: report a side effect.
Free to cite & embed
Journalists and researchers may reproduce the endpoint definitions, methodology, and any published result free of charge with attribution to Kindr Health. No permission request needed.
Citation (APA)
Because we do not have a completed cohort. Kindr Health publishes results only after a pre-registered cohort reaches its 12-week endpoint with follow-up accounted for. Publishing anything sooner would mean publishing numbers we could not defend. This page exists so the methodology is on the record before the results are — that is what makes the results credible.
Yes. The methodology, endpoint definitions, and every published result are free to cite, quote, and republish with attribution — no permission request needed. Use the citation block on this page.
Reviews are subjective self-reported experience, published unedited. The registry is structured clinical measurement against fixed instruments. Both are published; they answer different questions and we never present one as the other.
Yes. Adverse events reported through our pharmacovigilance intake are coded continuously and reported in aggregate each quarter, including events that led patients to stop treatment.
The Kindr Health Clinical Team reviews the protocol, endpoint definitions, and every published report before release.
Protocol reviewed by the Kindr Health Clinical Team · NPI 1609792902 · Last reviewed August 1, 2026. Press and data enquiries: press@kindr.health · media kit